Catalog No.: PC-70094Not For Human Use, Lab Use Only.
AZD-9056 is a potent, selective, orally bioavailable P2X7 receptor antagonist, inhibits release of pro-inflammatory mediators from isolated human peripheral monocytes (IL-1β and IL-18) and human alveolar macrophages (IL-1β) with IC50 values of 10-13 nM.
AZD-9056 is a potent, selective, orally bioavailable P2X7 receptor antagonist, inhibits release of pro-inflammatory mediators from isolated human peripheral monocytes (IL-1β and IL-18) and human alveolar macrophages (IL-1β) with IC50 values of 10-13 nM.
AZD-9056 displays >100-fold selectivity and specificity other P2X receptors.
AZD-9056 also is an inhibitor of BCRP and weakly inhibited BCRP-mediated transport of methotrexate (IC50=92 uM).
AZD-9056 significantly reduces disease severity in the streptococcal cell wall (SCW) model of arthritis.
